Introduction
With a prevalence of over 72.4% [1] , and as major symptom of the majority of diseases (trauma, inflammation, arthritis cancer), pain affects the entire world population. Nevertheless, understanding its signaling pathways, its transmission and maintenance, is important in improving its management [2] . Pain is a multifactorial disease which can affect different types of organs. Thus, without adequate treatment, acute pain can lead to chronic pain. It includes neuropathic and inflammatory pain which is the most frequent.
These pains are still regarded as a problem in medical practice and remain without satisfactory treatment [3, 4] . Chronic pain occurs as a consequence of alterations in the nerves (peripheral) and the central nervous system resulting in hyperalgesia and/or allodynia [5] [6] [7] .
The induction of chronic inflammatory pain with chemical such
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as carrageenan in rat causes initially the release of inflammatory mediators such as bradykinin followed by a synthesis of proinflammatory cytokines, prostaglandins and sympathetic amines [8] .
These mediators will induce the development of inflammatory nociception by decreasing pain threshold at the level of primary afferent neurons [9] . Moreover, during this process, there is an increase of intracellular guanosine monophosphate (cGMP) production by nitric oxide (NO) through the activation of guanylate cyclase. However, it is well documented that, anti-nociceptive effect is observed with L-arginine in the model of hyperalgesia caused by carrageenan in the rat, and this effect is inhibited in presence of NO and guanylyl cyclase (methylene blue) inhibitors [10, 11] . Equally in the same process, there is an opening of ATP-sensitive K + channels (K ATP ) mediated via the stimulation of protein kinase G by cGMP [12] .
Chronic consumption of chemotherapeutic agents such as vincristine in patient suffering cancer are known to induce the development of peripheral neuropathy in at least 30% to 40% of cases [13] [14] [15] [16] .
Pharmacological management of neuropathic pain includes anticonvulsants (gabapentin and carbamazepine), analgesics (tramadol and fentanyl patches) and tricyclic antidepressants (amitriptyline). Despite their limited effectiveness and side effects related to their use, these molecules remains the therapeutic option for neuropathic pain treatment [17, 18] . Thus, nowadays, it is important to found out new therapeutic agents for management of neuropathic with higher efficacy and less sides effects [19] .
Piptadeniastrum africanum (P. africanum), also called Piptadenia africana Hook. f., is a big tree belonging to the family Mimosaceae family. This plant is mostly founded in Senegal, Soudan, Ouganda, Congo, Northen Angola and Eastern Cameroon. Its stem bark is traditionally used in Cameroon for the treatment of ailments such as wounds, edema, constipation, aneamia, gastric ulcer, rheumatism, fever, pneumonia, meningitis, rheumatism and pain [20] [21] [22] . Studies on this plant revealed their antibacterial, antiulcerogenic activities [23] [24] [25] as well as antiproliferative, antinociceptive and anti-inflammatory properties [26, 27] . Also, our previous work on the same plant revealed it anti-arthritis effect [28] . The phytochemical analysis of P. africanum roots showed the presence of compounds such as saponins, alkaloids, triterpenoids, steroids and flavonoids [29] .
Based on the previous work, this work aims to determine the potential role of nitric oxide-cyclic-guanosine monophosphate-K + channels (NO-cGMP-K + ) and or endogenous opioids pathway in the analgesic process of methanol extract of stem bark of P. africanum using inflammatory pain model induced by carrageenan injection into rat paw. Also, it aims to evaluate the anti-hyperalgesic effect of extract in neuropathic pain model induced by vincristine.
Materials and methods

Experimental animals
Wistar rats (138) weighing in average 175 g (3 months age, both sexes) were used. Inflammatory pains assay was conducted with males while females were used in neuropathic pain induced model. were administered orally one hour before carrageenan induction.
Carrageenan-induced hyperalgesia
Mechanical hyperalgesia
The effect of PAME (250 and 500 mg/kg), diclofenac (50 mg/ kg) and vehicle (5% DMSO + PBS) on mechanical hyperalgesia was measured with the analgesimeter (UGO Basile, Italy) paw pressure [30, 31] . The hind paw of the rat, placed in a pressure applicator, was stimulated by increasing pressure (cut-off of 250 g) until vocalisation or withdrawal. The nociceptive threshold value was considered as the force (g) obtained.
Thermal hyperalgesia
The effect of PAME (250 and 500 mg/kg), diclofenac (50 mg/ kg) and vehicle (5% DMSO + PBS) on thermal hyperalgesia was evaluated with the UGO Basile plantar test apparatus (Italy) [32] .
Individually, the rat was introduced into a glass acrylic box (18 cm 伊8 cm伊8 cm). After habituation (10 min), a radiant heat stimulus (50 W) was projected on the paw through an opening (oval-shaped, maximum stimulation time of 20 s was used in case of non-reaction of the animal.
For each rat, mechanical and thermal hyperalgesia were performed before the oral administration of different treatments and carrageenan (0.1 mL, 2% dissolved in 0.9% NaCl) was injected 1 h after. Other measures of the thickness of the hind paw followed the injection of carrageenan, precisely 0.5, 1, 2, 3, 4, 5 and 6 h after.
PGE 2 -induced mechanical hyperalgesia
One hour after oral treatment of animal with 5% DMSO, PAME (500 mg/kg) or diclofenac (50 mg/kg), each animal received 0.1 nmol of PGE 2 by paw under the subplantar aponevreous. The frequency reaction to paw pressure stimulus was measured before PGE 2 injected and 1, 2, 3, 4, 5 and 6 h after PGE 2 was injected [33] . In another register, to verify the therapeutic effect, the medications were administered 1 h (orally) after PGE 2 and mechanical hyperalgesia was estimated in the same way [34] .
Involvement of NO/cGMP/K + pathway or participation of endogenous opioids
The contribution of NO/cGMP/K + pathway and/or endogenous opioids in the modulation of PAME anti-nociceptive activity were determine by the method described previously by Ding et al [35] and Mbiantcha et al [33] with small modifications. For each experiment, each animal was subject to a single use 60 min before carrageenan injection, PAME (500 mg/kg, p.o.) or the vehicle (10 mg/kg, p.o.)
used for dissolving PAME were given orally. Several antagonists and agonists substances were used to verify the participation or not of NO/cGMP/K + pathway and/or endogenous opioids in the modulation of PAME anti-nociceptive activity. Opioid antagonist and agonist (20 mg/kg of naloxone and 5 mg/kg of morphine, both i.p.), nitric oxide synthase inhibitor and substrate for nitric oxide synthase (90 mg/kg of L-NAME and 200 mg/kg L-arginine, both i.p.), soluble guanylyl cyclase inhibitor (1 mg/kg of methylene blue, i.p.) or K ATP -channel blocker and opener (5 mg/kg of glibenclamide and 2 mg/kg of diazoxide, both i.p.) pretreated groups of animals were added and the antagonists were given before (15 min) PAME. Sixty minutes after PAME administration, carrageenan test was carried out as described earlier. The dose selections for carrageenan (2%), the drugs (agonist and/or antagonist) were based on our preliminary investigation and from works references [33] .
Induction of neuropathic pain with vincristine and treatment
Vincristine-induced neuropathy in rats was performed as described [36] . Briefly, an intraperitoneal injection of 100 μg/kg of vincristine sulphate was administered to the rats during two series of five successive working days (days 1-5 and days 8-12) with 2 d off. Baseline measurements of the reaction latency of maximum force applied until paw withdrawals or vocalisations indicative of pain were taken 30 min after the injection of the vincristine using the Randall-Selitto test. The rats were divided into 3 groups of 6 rats each and were treated with PAME (500 mg/kg, p.o.), morphine (5 mg/kg, p.o.) or 5% DMSO (vehicle). Treatments were given from the first day before the injection of vincristine and continued daily until day 15.
Behavioral assessment of neuropathic pain
Three sets of pain assessment tests: mechanical hyperalgesia induced with an analgesiometer (UGO Basile, Italy), thermal hyperalgesia induced with the hot plate [(51±0.5) 曟 ] (Ugo Basile, Monvalle VA, Italy) and cold allodynia using cold water at 4 曟 were used to evaluate the analgesic effects of PAME in the vincristineinduced neuropathic pain on days 0, 1, 3, 5, 7, 9, 11, 13 and 15. Mechanical hyperalgesia induced by analgesiometer was performed as described earlier in the case of inflammatory pain.
Thermal hyperalgesia was performed in the rats after the vincristine-induced neuropathy using the hotplate as previously described [37] . Briefly, the animals were gently dropped onto the hot plate that was preheated to (51±0.5) 曟 and cut-off latency of 20 s was observed.
Cold hyperalgesia was evaluated by immersing the rat's tail into water at 4 曟 as previously described [38] . The inactivity for a rat to withdrawal its tail was determinate with a digital timer with a cut-off of 20 s and the duration of immersion was noted [33] .
Biochemical and hematological estimations
Anesthetic ether was administered to rats on day 16, the thoracic cavity was opened and through cardiac puncture, blood was collected into a tube filled with anticoagulant (EDTA) and used in determining Hematological parameters by usual Laboratory standard method [33] ;
while another free EDTA tube containing blood was centrifuged (4 900 rpm/5 min) to obtain serum, used for measurement of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and creatinine levels [39] .
Chemicals and drugs
L-arginine, L-NAME, methylene blue, glibenclamide, carrageenan, PGE 2 , diclofenac, morphine, diazoxide, naloxone chloridrate and DMSO were acquired from Sigma (Sigma Chemical Co., USA).
5% DMSO (DMSO + PBS) has been used to dissolve methylene blue, diclofenac, morphine and glibenclamide whereas carrageenan, L-NAME, diazoxide, naloxone chlorydrate and L-arginine were diluted in saline solution. PGE 2 (stock solution) was prepared in absolute ethanol (0.5 mg of PGE 2 for 1 mL ethanol) and diluted in sterile saline (less than 0.1% ethanol in the injected solution).
Statistical analysis
The data of this study (expressed as Mean 暲 standard error, n=6)
were statistically analyzed by Graph pad prism Version-5. 2 ). 
Effects of PAME on PGE 2 -induced mechanical hyperalgesia
After administration of PGE 2 into the paw, it developed a painful hypersensitivity in animals. PGE 2 -induced hyperalgesia was significantly (P<0.001) reduced by diclofenac and PAME after administration for preventive measures ( Figure 3A ). In addition, as revealed in Figure 3B , PAME as well as diclofenac significantly (P<0.001) inhibited PGE 2 ¬ induced hyperalgesia when given as a therapeutic scheme of treatment. In both cases ( Figure 3A and 3B) at the second hour, effect of PAME was more pronounced than that of diclofenac with inhibition percentage of 80.0% for extract, 38 .0% for diclofena in Figure 3A , 88.5% for extract and 61.0% for diclofenac in Figure 3B .
(50 mg/kg) Figure 3 . Effect of oral administration of PAME on mechanical hyperalgesia in PGE 2 (100 毺 L) inflamed rat paw.
In panel (A), animals were treated 1 h before PGE 2 injection and pain response was evaluated before treatment and after PGE 2 injection. In panel (B), treatments were given orally 1 h after PGE 2 and response to pain was evaluated before PGE 2 injection and after treatment. n=6; b P<0.01; c P<0.001 significantly different compared to vehicle. Figure 4 revealed the probable mechanisms implicated in antinociception effect of PAME. The effect of PAME or morphine or diazoxide was significantly canceled in animals having previously received L-NAME (inhibitor of nitric oxide synthase) ( Figure   4A ), methylene blue (inhibitor of guanylate Cyclase) ( Figure 4B ), glibenclamide (K ATP ¬channel blocker) ( Figure 4C ) or naloxone (opioid antagonist) ( Figure 4D ). L-arginine alone significantly (P<0.05) enhanced the anti-nociceptive effect of PAME ( Figure   4A ). 
Involvement of NO/cGMP/K + pathway or participation of endogenous opioids
Effect of PAME in neuropathic pain induced by vincristine
In all animals having received no treatment (vincristine + vehicle), a progressive increase of sensibility, installation of peripheral neuropathy characterize by an increase of mechanical, heat and tail cold hyperalgesia were observed ( Figures 5) . PAME or morphine, administered before injection of vincristine, significantly protected animals by preventing installation of hyperalgesia. This protection was significant against installation of mechanical and tail cold hyperalgesia from 6th day, then against heat hyperalgesia from 7th day. The protective effect of PAME against mechanical, heat and tail cold hyperalgesia was significantly higher than that of morphine. 
Effect of PAME on hematological and serum parameters
The significant increase (P<0.001) in levels of platelets, white blood cell (WBC) and the significant decrease in levels of red blood cell (RBC) (P<0.01), haemoglobin (Hb) (P<0.001) and hematocrit (P<0.05) were observed in untreated group. However, the treatment with PAME (500 mg/kg) and morphine (5 mg/kg) revealed an significant increase in Hb (P<0.05), RBC (P<0.05) and hematocrit (P<0.05). In a similar way, the PAME (500 mg/ kg) significantly reduced the increase of platelets (P<0.001) and WBC (P<0.01) and finally, their results were very close to those of animals of the normal control group (Table 1) .
Effect of PAME on biochemical parameters
As a result of vincristine-induced neuropathic pain, the serum levels of AST, ALT, ALP and creatinine were increased significantly (P<0.001) in control group. These enzyme levels were altered by treatment with PAME and morphine. The level of AST, ALT, ALP and creatinine were significantly (P<0.001) decreased by treatment with PAME (500 mg/kg) and morphine (5 mg/kg) ( Table 2 ).
Discussion
Our previous work on P. africanum extracts showed its analgesic properties on acute pain model (acetic acid, formalin and analgesimeter test) [27] and anti-arthritis effect induced by CFA administration in rats joint paw [28] . There is little evidence in the literature of P. africanum concerning analgesic properties. A study by Diffoum [27] reported that aqueous and methanol extracts of P.
africanum (250 and 500 mg/kg) reduced the latent period of hind paw leakage after formalin injection and the number of abdominal contractions after acetic acid injection; it is also reported that these extracts delay the time of withdrawal of the paw in normal animals on model of pain induced by pressure using ananalgesymeter. In the present study, the effects of PAME on thermal or mechanical hyperalgesia induced by carrageenan and PGE 2 , the importance of NO/cGMP/K + pathway or endogenous opioids receptors in this antinociceptive activity and the protective effect of the extract against the neuropathic pain induced by vincristine was shown.
The intra-plantar (i.pl) injection of carrageenan into the right paw of rats provoked a significant hypersensivity when compared with saline group. Administration of PAME (250 and 500 mg/ kg) as well as diclofenac (50 mg/kg) significantly reduced hypersensitivity in treated animals. The model of inflammatory hyperalgesia caused by subcutaneous injection of carrageenan into the paw of animals (preferably rodents) is widely used [40, 41] .
In this model, physiological and biochemical changes occurred over a short time course and limited to the affected limb [32] . After induction of inflammatory hyper-nociception, the receptors of primary nociceptor neurons are sensitized by the many mediators produced [42] . After injection of carrageenan, the production of TNF-毩 increases followed by that of IL-1 毬 and IL-6, then the level of PGE 2 increases by stimulation of COX followed by an increase in the production of IL-8 which stimulates the release of sympathetic amines [43, 44] . These inflammatory mediators produced after administration of carrageenan cause inflammatory pain and hyperalgesia by direct action on the target (receptors) present on peripheral terminations of neurons [45, 46] . Local changes, the development of secondary hyperalgesia followed by central changes are mainly caused by sensitization of the peripheral nociceptors of primary affections after carrageenan injection [47, 48] . In addition the central sensitization that occurs causes the development and maintenance of the chronic phase of hyperalgesia [49, 50] . Herein, our results revealed that, PAME significantly reduced the mechanical hyperalgesia caused by carrageenan (intra-plantar injection). In Addition, the anti-nociceptive activity of PAME was preserved until the 6th hour. These results indicate that PAME interferes with pain sensitivity (acute) as well as the expression of many mediators Table 1 Influence of PAME on hematological parameters after vincristine induced neuropathic pain in rats. Effect of PAME on biochemical parameters in vincristine induced neuropathic pain in rats. including prostaglandins. PAME were tested on the hyperalgesia model induced by PGE 2 . After injection of PGE 2 , prostanoid peripheral nerve receptors are sensitized resulting in activation of protein kinase A followed by hyperalgesia development [51, 52] . In addition the presence of PGE 2 leads to an increase in the production of NO which leads to an increase in capillary permeability and vasodilatation with consequent development of the sensitivity of painful fibers and edema [53] . The results obtained in this part show that, the anti-nociceptive activity of PAME is higher when the PGE 2 is administered after treatment.
These results lead us to think that PAME would act on prostaglandin receptors, and the cascade of biochemical reactions involved after activation of the receptors of PGE 2 . In the order to verify the participation of the opioids and the NO/cGMP/K + pathways in the analgesic activity of PAME, several antagonists and agonists substances were used as previously described.
The results reveal that, the antinociceptive activity of PAME is associated to an important implication of the endogenous opioid pathway. This is justified by the fact that, the presence of naloxone significantly reduces the antinociceptive effect of PAME. It is known that, opioid agonists such as morphine cause the opening of sensitive potassium channels after their binding to opioid receptors [54] . In addition, activation of NO/cGMP pathway with opening of ATP¬ sensitive K + channel play an important role in the mechanism of anti-nociception of morphine [55, 56] . To verify this option, we studied the effect of various antagonists on PAME antinociception, namely L-NAME, MB, glibenclamide, respectively known as inhibitor of nitric oxide synthase, guanylyl cyclase inhibitor and blocker of K + ATP -channels. Interestingly, the result revealed that, pre-treatment of rats with L-NAME, MB or glibenclamide, significantly reversed the anti-nociceptive effects of PAME. These data confirm the hypothesis that, PAME could induced it anti-nociceptive activity by fixing on opioid receptors and activating the NO/cGMP signaling pathway, causing an opening of K + channels. This observation corroborate the results obtained by Negrete et al [57] , in which they demonstrated that, in inflammatory state, local analgesic effects observed by opioid administration is mainly mediated through the stimulation of the peripheral nitric oxide-cGMP-protein kinase G (PKG)-ATPsensitive K + (KATP) channels signaling pathway. Moreover, the analgesic activities induced by compounds such as diclofenac and dipyrone are also known to interfering with NO/cGMP/K + pathways [58] [59] [60] . It can then be suggested that, PAME inhibits acute inflammatory pain by interfering with PGE 2 , opioid and NO/ cGMP/K + pathways. So, another probability is that, PAME might prevent chronic pain. This suggestion was assessed by testing PAME on vincristine-induced neuropathic pain.
Vincristine is an antineoplastic agent commonly used for the treatment of a number of cancer, including Hodgkin's disease and small cell lung cancer [61] . Its major limiting side effect is peripheral neuropathy [62, 63] . Pretreatment with PAME significantly reduced mechanical hyperalgesia and cold allodynia induced by vincristine administration. This important activity was observed and conserved during the 14 days of treatment. These results corroborate those obtained in acute inflammatory pain. Moreover, phytochemical study of methanolic extract of PAME revealed the presence of compounds such as oleanic acid which is a pentacyclic triterpene known for its analgesic, antioxidant and anti-inflammatory activity [64, 65] . So, the analgesic effect of PAME may be partially due to the presence of that compound.
Cancer causes the death of one fifth of the population and it is difficult today to prevent or heal it. So, the treatment available nowadays presents many side effects in particular hematological effects [66] . Secondary hematological effects has reached the anti-cancer chemotherapy in humans are the same order as that found in rats [67] . Lahouel et al [68] and Raguenez-Viotte et al [69] have demonstrated that, after administration of anticancer drugs (doxorubicine, belustine) in rats, single dose are capable to induce hematological disorder. This hematological toxicity was observed with all anticancer drugs [70] , even those for natural origin such as vincristine [66] . In addition, Upmanyu et al [71] showed that, the administration of vincristine in rats causes an important increase in serum enzyme levels such as ALT, AST and ALP. It is clear from our investigation that, the levels of platelets, WBC, AST, ALT, ALP and creatinine were increased significantly and the levels of RBC, hematocrit and Hb were significantly decreased in non-treated group. PAME or morphine treated group significantly improved the level of all hematological (platelets, WBC, RBC, Hb and hematocrit) and biochemical (AST, ALT, ALP and creatinine) parameters compared to non-treated group. These results suggest that, oral administration of PAME not only protect against the neuropathic pain development but also prevent the development of side effects (hematologic and hepatic) induced by vincristine administration.
The evidences presented here suggest that, PAME when given orally possesses anti-nociceptive properties against inflammatory and neuropathic pain. The data obtained also confirm the involvement of opioid and NO/cGMP/K + pathways in its analgesic effect and can justify its used in Cameroonian folks medicine.
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